The Evaluation of Orphan Drugs by the German Joint Federal Committee-An Eight-Year Review
- PMID: 33612156
- PMCID: PMC8025936
- DOI: 10.3238/arztebl.2020.0868
The Evaluation of Orphan Drugs by the German Joint Federal Committee-An Eight-Year Review
Figures
References
- 
    - Schulz S, Passon A, Kulig M, Perleth M, Matthias K. Studien bei seltenen Erkrankungen: eine deskriptive Analyse abgeschlossener Orphan Drug Bewertungen im Gemeinsamen Bundesausschuss. Gesundheitswesen. 2018;80:e54–e61. - PubMed
 
- 
    - Gemeinsamer Bundesausschuss. Verfahren der Nutzenbewertung nach § 35a SGB V. www.g-ba.de/bewertungsverfahren/nutzenbewertung/ (last accessed on 1 April 2020)
 
- 
    - Sarpatwari A, Kesselheim AS. Reforming the orphan drug act for the 21st Century. N Engl J Med. 2019;381:106–108. - PubMed
 
- 
    - Europäische Kommission. Proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending directive 2011/24/EU. www.ec.europa.eu/health/sites/health/files/technology_assessment/docs/co... (last accessed on 4 June 2020)
 
MeSH terms
LinkOut - more resources
- Full Text Sources
 
         
              